Itau Unibanco Holding S.A. Makes New Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Itau Unibanco Holding S.A. purchased a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 327 shares of the biopharmaceutical company’s stock, valued at approximately $79,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Gilbert & Cook Inc. increased its holdings in Alnylam Pharmaceuticals by 7.7% in the fourth quarter. Gilbert & Cook Inc. now owns 4,443 shares of the biopharmaceutical company’s stock worth $850,000 after buying an additional 317 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Alnylam Pharmaceuticals by 6.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 267,034 shares of the biopharmaceutical company’s stock valued at $51,126,000 after purchasing an additional 15,123 shares in the last quarter. Envestnet Portfolio Solutions Inc. lifted its stake in shares of Alnylam Pharmaceuticals by 7.0% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 1,368 shares of the biopharmaceutical company’s stock valued at $262,000 after purchasing an additional 89 shares during the last quarter. Robeco Institutional Asset Management B.V. lifted its stake in shares of Alnylam Pharmaceuticals by 155.7% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 12,513 shares during the last quarter. Finally, Assetmark Inc. boosted its holdings in Alnylam Pharmaceuticals by 19.6% in the fourth quarter. Assetmark Inc. now owns 6,913 shares of the biopharmaceutical company’s stock worth $1,323,000 after purchasing an additional 1,135 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 15,000 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $280.00, for a total value of $4,200,000.00. Following the completion of the transaction, the chief executive officer now owns 73,441 shares in the company, valued at $20,563,480. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, Director Dennis A. Ausiello sold 20,250 shares of the firm’s stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $262.00, for a total value of $5,305,500.00. Following the completion of the sale, the director now directly owns 136 shares in the company, valued at $35,632. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Yvonne Greenstreet sold 15,000 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $280.00, for a total value of $4,200,000.00. Following the completion of the transaction, the chief executive officer now directly owns 73,441 shares of the company’s stock, valued at $20,563,480. The disclosure for this sale can be found here. Insiders have sold a total of 70,698 shares of company stock worth $18,497,434 over the last ninety days. Corporate insiders own 1.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on ALNY. UBS Group boosted their price target on Alnylam Pharmaceuticals from $253.00 to $288.00 and gave the stock a “buy” rating in a research report on Friday, June 28th. Raymond James upped their target price on Alnylam Pharmaceuticals from $242.00 to $275.00 and gave the stock an “outperform” rating in a research report on Friday, August 2nd. Canaccord Genuity Group lifted their price target on shares of Alnylam Pharmaceuticals from $357.00 to $366.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. Leerink Partners upped their price objective on shares of Alnylam Pharmaceuticals from $138.00 to $159.00 and gave the stock a “market perform” rating in a report on Tuesday, June 25th. Finally, Stifel Nicolaus lifted their target price on shares of Alnylam Pharmaceuticals from $215.00 to $295.00 and gave the stock a “buy” rating in a report on Thursday, June 27th. Seven research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $279.14.

Alnylam Pharmaceuticals Trading Down 0.9 %

Shares of ALNY opened at $273.88 on Monday. The stock has a market cap of $34.64 billion, a PE ratio of -102.19 and a beta of 0.38. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $287.55. The stock has a 50 day simple moving average of $260.11 and a 200-day simple moving average of $199.42.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.61. The company had revenue of $659.83 million for the quarter, compared to the consensus estimate of $447.22 million. During the same period in the previous year, the business posted ($2.21) earnings per share. The firm’s revenue was up 107.0% compared to the same quarter last year. On average, sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.73 EPS for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.